Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

138.74 +1.90 (+1.39%)
Streaming Delayed Price Updated: 12:53 PM EDT, Aug 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation.
While growth is established for NASDAQ:NBIX, the stock's valuation remains reasonable. 
Via Chartmill
Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade
On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84. 
Via Investor's Business Daily
The 3 Most Undervalued Biotech Stocks to Buy in December
Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks. 
Via InvestorPlace
Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up Days
Cassava Sciences sees its Relative Strength Rating reach the 80-plus level. 
Via Investor's Business Daily
Are These Biotechs Ready To Launch?
Biotech stocks are still in the process of repairing the damage from recent months — and recent years. Indeed, as of a month ago, the SPDR Biotech Fund had been dead money for an unbelievable eight and... 
Via Talk Markets
TG Therapeutics Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating
TG Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 87 to 93. 
Via Investor's Business Daily
Analyst Expectations for Neurocrine Biosciences's Future
 
Via Benzinga
NASDAQ:NBIX: a strong growth stock preparing for the next leg up?.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?. 
Via Chartmill
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank.
Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise
Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
Investors seeking growth at a reasonable cost should explore NASDAQ:NBIX.
Investors seeking growth at a reasonable cost should explore NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). 
Via Chartmill
CRISPR Therapeutics Stock Earns 88 RS Rating On U.K. Regulator News
CRISPR Therapeutics sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating
Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86. 
Via Investor's Business Daily
Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade
Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 93 the day before. 
Via Investor's Business Daily
Why Is Neurocrine Biosciences Stock Trading Lower Today?
Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX)  
Via Benzinga
NASDAQ:NBIX: a strong growth stock preparing for the next leg up?.
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
Earnings Outlook For Neurocrine Biosciences
 
Via Benzinga
NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move.
Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
3 Biotech Moonshots to Bet on the Future of Health
Thanks to their potential blockbuster drugs, these three biotech stocks may yield huge returns for patent investors willing to take the risk. 
Via InvestorPlace
Topics Intellectual Property
Rocket Pharmaceuticals Stock Sees Improved Price Strength
On Thursday, Rocket Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 78 
Via Investor's Business Daily
Raymond James Maintains Outperform Rating for Neurocrine Biosciences: Here's What You Need To Know
 
Via Benzinga
Despite its growth, NASDAQ:NBIX remains within the realm of affordability.
Don't overlook NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
What 22 Analyst Ratings Have To Say About Neurocrine Biosciences
 
Via Benzinga
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
NASDAQ:NBIX: a strong growth stock preparing for the next leg up?.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?. 
Via Chartmill
NASDAQ:NBIX qualifies as a high growth stock and is consolidating.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
Why Is Neurocrine Biosciences Shares Trading Higher Today?
Neurocrine Biosciences Inc (NASDAQ: NBIX) released topline data from the Phase 3 CAHtalyst Pediatric Study of crinecerfont in children and adolescents with classic congenital adrenal hyperplasia (CAH)... 
Via Benzinga
Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation.
Why NEUROCRINE BIOSCIENCES INC ( NASDAQ:NBIX ) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
Analyst Expectations for Neurocrine Biosciences's Future
 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.